Repligen Corporation
RGEN
$155.70
-$4.41-2.75%
| Weiss Ratings | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Weak | |||
| Risk Index | Weak | |||
| Risk Grade | D | |||
| Reward Grade | D+ | |||
| Rating Factors | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Fair | |||
| Solvency Index | Excellent | |||
| Total Return Index | Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.54 | |||
| Price History | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.37% | |||
| 30-Day Total Return | -7.27% | |||
| 60-Day Total Return | 4.36% | |||
| 90-Day Total Return | 15.18% | |||
| Year to Date Total Return | 8.84% | |||
| 1-Year Total Return | -21.55% | |||
| 2-Year Total Return | -15.84% | |||
| 3-Year Total Return | -4.86% | |||
| 5-Year Total Return | 70.20% | |||
| 52-Week High % Change | -21.18% | |||
| 52-Week Low % Change | 41.07% | |||
| Price | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $203.13 | |||
| 52-Week Low Price | $113.50 | |||
| 52-Week Low Price (Date) | Jun 20, 2024 | |||
| 52-Week High Price (Date) | Mar 08, 2024 | |||
| Valuation | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 8.97B | |||
| Enterprise Value | 8.86B | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -0.15 | |||
| Earnings Per Share Growth | -108.31% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | 14.16 | |||
| Price/Book (Q) | 4.45 | |||
| Enterprise Value/Revenue (TTM) | 13.98 | |||
| Price | $155.70 | |||
| Enterprise Value/EBITDA (TTM) | 94.00 | |||
| Enterprise Value/EBIT | 344.81 | |||
| Market Cap Category | Mid Cap | |||
| Dividends and Shares | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 56.01M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 781 250 0111 | |||
| Address | Building 1 Waltham, MA 02453 | |||
| Website | www.repligen.com | |||
| Country | United States | |||
| Year Founded | 1981 | |||
| Profitability | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | 4.05% | |||
| Profit Margin | -1.27% | |||
| Management Effectiveness | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | 0.60% | |||
| Return on Equity | -- | |||
| Income Statement | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | 633.51M | |||
| Total Revenue (TTM) | 633.51M | |||
| Revenue Per Share | $11.31 | |||
| Gross Profit (TTM) | 324.52M | |||
| EBITDA (TTM) | 94.24M | |||
| EBIT (TTM) | 25.69M | |||
| Net Income (TTM) | -8.10M | |||
| Net Income Avl. to Common (TTM) | -8.10M | |||
| Total Revenue Growth (Q YOY) | 9.69% | |||
| Earnings Growth (Q YOY) | -103.86% | |||
| EPS Diluted (TTM) | -0.15 | |||
| EPS Diluted Growth (Q YOY) | -103.90% | |||
| Balance Sheet | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 783.96M | |||
| Cash Per Share (Q) | $14.00 | |||
| Total Current Assets (Q) | 1.13B | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | 2.02B | |||
| Current Ratio (Q) | 10.442 | |||
| Book Value Per Share (Q) | $36.00 | |||
| Total Assets (Q) | 2.83B | |||
| Total Current Liabilities (Q) | 108.37M | |||
| Total Debt (Q) | 672.47M | |||
| Total Liabilities (Q) | 813.96M | |||
| Total Common Equity (Q) | 2.02B | |||
| Cash Flow | RGEN - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -191.53M | |||
| Cash from Financing (TTM) | 183.78M | |||
| Net Change in Cash (TTM) | 153.19M | |||
| Levered Free Cash Flow (TTM) | 138.31M | |||
| Cash from Operations (TTM) | 165.28M | |||
